Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.54 |
| ▸ | PREP | P48147 | 5/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1348449 | 0.99 | DPP4 (0.58) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL8295116 | 0.86 | DPP4 (0.71) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL5152227 | 0.84 | DPP4 (0.50) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1019926 | 0.83 | DPP4 (0.40) | DPP4DPP8DPP7PREPDPP9 | |
| Hydrochloric Acid SCHEMBL1022579 | 0.83 | DPP4 (0.39) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL5222258 | 0.77 | DPP4 (0.73) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL5149169 | 0.76 | DPP4 (0.61) | DPP4DPP8DPP7PREPDPP9 | |
| Hydrochloric Acid SCHEMBL5205598 | 0.75 | DPP4 (0.97) | DPP4 | |
| SCHEMBL1021491 | 0.74 | DPP4 (0.52) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL8267018 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | claimed |
| US-7655663-B2 | Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity | SANOFI-AVENTIS (FR) | 2010-02-02 | — | — | US | claimed |
| EP-1487807-B1 | Cyano-pyrrolidines as DPP-IV inhibitors | SANOFI AVENTIS (FR) | 2009-09-16 | — | — | EP | claimed |
| US-20080161310-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | US | claimed |
| US-20050130981-A1 | Compounds | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | US | claimed |
| US-8063045-B2 | Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| US-7655663-B2 | Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity | SANOFI-AVENTIS (FR) | 2010-02-02 | — | — | US | disclosed |
| EP-1487807-B1 | Cyano-pyrrolidines as DPP-IV inhibitors | SANOFI AVENTIS (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-20080161310-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | US | disclosed |
| US-7348327-B2 | Compounds | SANOFI-AVENTIS (FR) | 2008-03-25 | — | — | US | disclosed |
| US-7186731-B2 | 2-cyanopyrrolidinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7186731-B2 | 2-cyanopyrrolidinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20050130981-A1 | Compounds | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2005042533-A2 | 2-CYANOPYRROLIDINECARBOXAMIDES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161310-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-20050130981-A1 | Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.